A New Era in Drug Discovery…
NO TAGS, NO SURFACE ATTACHMENT FOR TRUE BINDING CHARACTERIZATION
Molecular Sensing, Inc. (MSI) is commercializing Back-Scattering Interferometry (BSI), the world’s first label-free, conformation-sensitive, free-solution assay technology for biophysical characterization of small molecule interactions with complex drug targets. This includes crude membrane protein preparations and other biochemically intractable target binding assays in native-like, free-solution environments — no tags or tethering.
Conformational change is the hallmark of protein dynamics and is intimately related to protein function. BSI detects binding-induced target conformational change with high specificity and sensitivity.
This TrueBind™ Technology allows unlabeled binding affinity measurement, target engagement verification and mechanism-of-action elucidation in a single assay platform, vital to informing pharmacology and medicinal chemistry drug discovery efforts.
TruBind Technology offers solutions for complex and intractable targets including:
• Label-free, in-solution, tether-free
• Conformational change specificity
• Complex matrix-tolerant
• Mass-independent binding affinity
• Radiolabel-level sensitivity
• Low sample consumption
• Streamlined assay development
MSI currently offers the TrueBind BSI System 100, a label-free optical measurement technique that senses conformation-based changes upon ligand binding to a target.
Pharmaceutical companies can also take advantage of TruBind Assay Services, a powerful, cost-effective outsourcing solution for high value drug discovery projects while enabling early access to the power of BSI technology.
KEY APPLICATIONS OF BSI TECHNOLOGY
Direct binding quantification of low molecular weight ligands to ortho- and allosteric integral membrane protein and protein complex binding sites, under conditions where other technologies fail.
Direct binding confirmation of drug candidates from an HTS screen to the target of interest is critical to verification of a suspected MOA.
Complex drug targets for a large range of target classes have been successfully characterized in projects with major pharmaceutical companies.